Abstract
Novel therapeutic options for patients with recurrent primary central nervous system lymphoma (RPCNSL) are needed. Bendamustine, a bifunctional purine analog/alkylating agent, is approved for use in patients with progressive systemic indolent non-Hodgkin's B-cell lymphomas. Limited data suggests that bendamustine may partition into the brain in the setting of a disrupted blood-brain barrier. This report describes the first known experience of patients with RPCNSL treated with bendamustine. Therapy was well-tolerated and best response was noted as stable disease after eight cycles of bendamustine followed by a subsequent local systemic recurrence found at five months follow-up. CNS involvement in this patient remained stable 20 + months post-bendamustine treatment. Based on our observations, further neuropharmacokinetic and efficacy studies with bendamustine may be warranted in this patient population.
Original language | English (US) |
---|---|
Pages (from-to) | 659-663 |
Number of pages | 5 |
Journal | Journal of Neuro-Oncology |
Volume | 107 |
Issue number | 3 |
DOIs | |
State | Published - May 2012 |
Externally published | Yes |
Keywords
- Bendamustine
- Chemotherapy
- Recurrent primary CNS lymphoma
ASJC Scopus subject areas
- Oncology
- Neurology
- Clinical Neurology
- Cancer Research